Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924961 | 0.78 | CYP1A2 (0.42) | PIK3CBGRIN2B | |
| SCHEMBL21088711 | 0.77 | GRIN2B (0.36) | PIK3CBGRIN2BGRIN1MAOB | |
| SCHEMBL2371256 | 0.77 | HSD17B10 (0.44) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL23346665 | 0.77 | PIK3CB (0.49) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL19152184 | 0.77 | HPGD (0.44) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL22155718 | 0.76 | PIK3CB (0.40) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL22152275 | 0.74 | PIK3CB (0.39) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL25037437 | 0.74 | PIK3CB (0.39) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL19759412 | 0.74 | PIK3CB (0.39) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL18228366 | 0.73 | PIK3CB (0.38) | PIK3CBGRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | ALPI, UROD, HLA-C | PIK3CB 3557/4885GRIN2B 4551/4885GRIN1 4090/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | PIK3CB 3312/4885GRIN2B 2674/4885GRIN1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.